James M. Rae
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
293
Citations
11,367
Est. group size
~44
Recurring co-author estimate
Active years
46
Publishing since 1981
Typically publishes in teams of ~12 · 15% small-team papers (≤3 authors) · across 24 venues
- Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial.
Journal of Clinical Oncology · 2025
- Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer
Journal of Clinical Oncology · 2024
- Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation
JAMIA Open · 2024
- Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms
Pharmacogenetics and Genomics · 2024
- Making Metastatic Breast Cancer Count
The Breast · 2024
- Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
Journal of Clinical Oncology · 2024
- New Earth system modelling constraints on marine carbonate chemistry and <i>p</i>>CO<sub>2</sub> in the geologic past <i>- R. Berner Lecture</i>>
2024
- Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
Biomarkers · 2023
- Data from Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT
2023
- Table S2 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
2023
- Table S1 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
2023
- Table S2 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
2023
- Figure S1 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
2023
- Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
2023
- Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
2023
- Cancer Research×24
- Journal of Clinical Oncology×11
- Pharmacogenomics×9
- Breast Cancer Research and Treatment×8
- Clinical Cancer Research×6
- Christina L. Gersch
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Thomas Helland
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Lynn M. Lerner
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Santosh Philips
Biochemistry, Genetics and Molecular Biology · Indiana University
- Todd C. Skaar
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile